Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Opening Session Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jun
19
Today In Oncology
AGA Advises Colonoscopy Over Alternate CRC Screening Methods
Overall Survival With EBRT in Hepatocellular Carcinoma
HCC TACE Plus STRIDE With or Without Lenvatinib
St Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally
FDA Warns of Ongoing Breast Biopsy Needle Shortage
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo